Unversity Medical Center Groningen
Welcome,         Profile    Billing    Logout  
 4 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Huls, Gerwin G
AML21, NCT02172872 / 2014-001486-27: "InDACtion" vs "3+7" Induction in AML

Active, not recruiting
3
606
Europe, RoW
standard combination chemotherapy, "3+7" induction chemotherapy, Intensive combined chemotherapy, decitabine, Dacogen
European Organisation for Research and Treatment of Cancer - EORTC, Janssen Pharmaceuticals, Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia (AML)
03/22
12/23
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Recruiting
3
415
Europe
Revumenib, Placebo
Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network
Acute Myeloid Leukemia, Adult
12/29
07/31
HO155, NCT04097470 / 2018-000047-31: Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Active, not recruiting
2
140
Europe
Decitabine, Dacogen, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Swiss Group for Clinical Cancer Research
AML/MDS
11/21
11/26
AFFECT-2, NCT04099901 / 2018-005046-10: Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial

Completed
2
88
Europe
Anakinra, Kineret, Placebos
Radboud University Medical Center, University Medical Center Groningen, Dutch Cancer Society
Multiple Myeloma
03/23
02/24
NCT05949125: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Recruiting
1
80
Europe
Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment
AvenCell Europe GmbH, Allucent (NL) BV
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
05/27
01/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Huls, Gerwin G
AML21, NCT02172872 / 2014-001486-27: "InDACtion" vs "3+7" Induction in AML

Active, not recruiting
3
606
Europe, RoW
standard combination chemotherapy, "3+7" induction chemotherapy, Intensive combined chemotherapy, decitabine, Dacogen
European Organisation for Research and Treatment of Cancer - EORTC, Janssen Pharmaceuticals, Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia (AML)
03/22
12/23
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Recruiting
3
415
Europe
Revumenib, Placebo
Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network
Acute Myeloid Leukemia, Adult
12/29
07/31
HO155, NCT04097470 / 2018-000047-31: Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Active, not recruiting
2
140
Europe
Decitabine, Dacogen, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Swiss Group for Clinical Cancer Research
AML/MDS
11/21
11/26
AFFECT-2, NCT04099901 / 2018-005046-10: Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial

Completed
2
88
Europe
Anakinra, Kineret, Placebos
Radboud University Medical Center, University Medical Center Groningen, Dutch Cancer Society
Multiple Myeloma
03/23
02/24
NCT05949125: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Recruiting
1
80
Europe
Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment
AvenCell Europe GmbH, Allucent (NL) BV
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
05/27
01/28

Download Options